Policy Developments - Hunan Province has issued an implementation plan to promote provincial-level coordination of basic medical insurance, aiming to enhance the level of medical security and the fund's risk resistance by 2029 [2] Drug and Device Approvals - Zai Lab has received approval for clinical trials of injectable ZGGS18 and ZG005 for use in advanced solid tumors, although this will not significantly impact the company's recent performance [4] - Jianfeng Group has voluntarily withdrawn its clinical trial application for "C2235 and C2235 tablets," with plans to resubmit after further research [5] Capital Markets - WuXi AppTec has made a conditional cash acquisition offer of HKD 4.00 per share for all shares of Dongyao Pharmaceutical, representing a premium of approximately 114.67% over the average closing price for the last 30 trading days [7] - Yinuo Micro Pharmaceuticals has submitted a listing application to the Hong Kong Stock Exchange, with Citigroup and CICC as joint sponsors [8] Industry Events - Over 11,000 designated medical institutions are equipped to purchase 105 new drugs added to the medical insurance catalog for 2025, with 6,537 being medical institutions and 4,592 retail pharmacies [10][11] - France has launched a roadmap to address national obesity issues, setting four key objectives to curb obesity growth and improve health outcomes [12] Public Opinion Alerts - Sunflower has been investigated by the China Securities Regulatory Commission for misleading statements in its restructuring plan, leading to a 20% drop in its stock price [14]

Policy Developments - Hunan Province has issued an implementation plan to promote provincial-level coordination of basic medical insurance, aiming to enhance the level of medical security and fund risk resistance by 2029 [1] Drug and Device Approvals - Zai Lab has received clinical trial approval for injectable ZGGS18 and ZG005 for use in advanced solid tumors, although this will not significantly impact the company's recent performance [2] - Jianfeng Group has voluntarily withdrawn its clinical trial application for "C2235 and C2235 tablets," with plans to resubmit after further research [3] Capital Markets - WuXi AppTec has made a conditional cash acquisition offer of HKD 4.00 per share for all shares of Dongyao Pharmaceutical, representing a premium of approximately 114.67% over the average closing price for the previous 30 trading days [4] - Yinuo Micro Pharmaceuticals has submitted a listing application to the Hong Kong Stock Exchange, with Citigroup and CICC as joint sponsors [5] Industry Developments - Over 11,000 designated medical institutions are equipped to purchase 105 new drugs added to the 2025 medical insurance catalog, with 6,537 being medical institutions and 4,592 retail pharmacies [6][7] - France has launched a roadmap for addressing national obesity issues, with goals to curb obesity growth, improve health conditions, enhance accessibility to personalized medical services, and support innovative care methods from 2026 to 2030 [8] Public Opinion Alerts - Sunflower has been investigated by the China Securities Regulatory Commission for alleged misleading statements in its restructuring plan, leading to a 20% drop in its stock price [9]

Core Viewpoint - Zhejiang Jianfeng Group Co., Ltd. announced that its subsidiary, Jianfeng Pharmaceutical, has voluntarily withdrawn the clinical trial application for the drug "C2235 and C2235 tablets" to the National Medical Products Administration, pending further research and will resubmit the application at a later date [2][3]. Group 1: Drug Registration and Withdrawal - Jianfeng Pharmaceutical received a termination notice for the drug registration application for "C2235 and C2235 tablets" from the National Medical Products Administration, indicating that the withdrawal was a proactive decision by the company [2]. - The withdrawal was due to the need for further improvement of the application materials during the registration process [2]. Group 2: Impact on Company Performance - The withdrawal of the clinical trial application for "C2235 and C2235 tablets" is not expected to have a significant impact on the company's current performance [3]. - The company acknowledges that the research and development of innovative drugs involve high technology and risks, with long and complex cycles from development to production, which are susceptible to unpredictable factors [3].

Core Viewpoint - The company announced that its wholly-owned subsidiary, Jianfeng Pharmaceutical, has received a termination notice from the National Medical Products Administration regarding the drug registration application for "C2235 and C2235 tablets," which was voluntarily withdrawn by the company to improve related research before resubmitting the clinical trial application [1] Group 1 - Jianfeng Pharmaceutical received a termination notice for the drug registration application for "C2235 and C2235 tablets" [1] - The withdrawal of the application is a proactive measure by the company to enhance its research [1] - The withdrawal of the clinical trial application will not have a significant impact on the company's current performance [1]